Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
66 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Cervical Dysplasia - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cervical Dysplasia - Pipeline Review, H2 2014', provides an overview of the Cervical Dysplasia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cervical Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Dysplasia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cervical Dysplasia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cervical Dysplasia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cervical Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cervical Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cervical Dysplasia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cervical Dysplasia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cervical Dysplasia Overview 6 Therapeutics Development 7 Pipeline Products for Cervical Dysplasia - Overview 7 Pipeline Products for Cervical Dysplasia - Comparative Analysis 8 Cervical Dysplasia - Therapeutics under Development by Companies 9 Cervical Dysplasia - Therapeutics under Investigation by Universities/Institutes 10 Cervical Dysplasia - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Cervical Dysplasia - Products under Development by Companies 13 Cervical Dysplasia - Products under Investigation by Universities/Institutes 14 Cervical Dysplasia - Companies Involved in Therapeutics Development 15 CEL-SCI Corporation 15 Helix BioPharma Corp. 16 Inovio Pharmaceuticals, Inc. 17 PDS Biotechnology Corporation 18 VLPbio 19 Cervical Dysplasia - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 CerviVax - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CIGB-228 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 interferon alpha-2b (recombinant) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Leukocyte Interleukin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PDS-0101 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 VGX-3100 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Cervical Dysplasia - Recent Pipeline Updates 40 Cervical Dysplasia - Dormant Projects 53 Cervical Dysplasia - Discontinued Products 54 Cervical Dysplasia - Product Development Milestones 55 Featured News & Press Releases 55 Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 55 Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 56 Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial 57 Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 57 May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 59 Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 59 Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 60 Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 61 Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 62 May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 63 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 66 Disclaimer 66
List of Tables Number of Products under Development for Cervical Dysplasia, H2 2014 7 Number of Products under Development for Cervical Dysplasia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Products under Development by Companies, H2 2014 13 Products under Investigation by Universities/Institutes, H2 2014 14 Cervical Dysplasia - Pipeline by CEL-SCI Corporation, H2 2014 15 Cervical Dysplasia - Pipeline by Helix BioPharma Corp., H2 2014 16 Cervical Dysplasia - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 17 Cervical Dysplasia - Pipeline by PDS Biotechnology Corporation, H2 2014 18 Cervical Dysplasia - Pipeline by VLPbio, H2 2014 19 Assessment by Monotherapy Products, H2 2014 20 Number of Products by Stage and Target, H2 2014 22 Number of Products by Stage and Mechanism of Action, H2 2014 24 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Cervical Dysplasia Therapeutics - Recent Pipeline Updates, H2 2014 40 Cervical Dysplasia - Dormant Projects, H2 2014 53 Cervical Dysplasia - Discontinued Products, H2 2014 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.